|
US5262564A
(en)
|
1992-10-30 |
1993-11-16 |
Octamer, Inc. |
Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
|
|
EP1466906A1
(en)
|
1999-03-12 |
2004-10-13 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Heterocyclic urea and related compounds useful as anti-inflammatory agents
|
|
NZ528846A
(en)
|
1999-03-12 |
2005-05-27 |
Boehringer Ingelheim Pharma |
Compounds useful as anti-inflammatory agents
|
|
EP1690854A1
(en)
|
1999-03-12 |
2006-08-16 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Heterocyclic urea and related compounds useful as anti-inflammatory agents
|
|
ATE285821T1
(de)
|
1999-10-08 |
2005-01-15 |
Affinium Pharm Inc |
Fab i inhibitoren
|
|
US6703525B2
(en)
|
2000-02-16 |
2004-03-09 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Sulfonamide intermediates and methods of producing same
|
|
US6608052B2
(en)
|
2000-02-16 |
2003-08-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compounds useful as anti-inflammatory agents
|
|
CA2444597A1
(en)
|
2001-04-06 |
2002-10-06 |
Affinium Pharmaceuticals, Inc. |
Fab i inhibitors
|
|
MXPA03009361A
(es)
|
2001-04-13 |
2004-01-29 |
Boehringer Ingelheim Pharma |
Compuestos de urea utilies como agentes anti-inflamatorios.
|
|
EP1395561A1
(en)
|
2001-05-25 |
2004-03-10 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Carbamate and oxamide compounds as inhibitors of cytokine production
|
|
JP2005503400A
(ja)
|
2001-09-13 |
2005-02-03 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
サイトカイン媒介病の治療方法
|
|
DE60226756D1
(de)
|
2001-10-04 |
2008-07-03 |
Merck & Co Inc |
Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5
|
|
US20050101518A1
(en)
|
2002-01-18 |
2005-05-12 |
David Solow-Cordero |
Methods of treating conditions associated with an EDG-2 receptor
|
|
ES2251677T3
(es)
|
2002-01-22 |
2006-05-01 |
Warner-Lambert Company Llc |
2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
|
|
JPWO2003062234A1
(ja)
|
2002-01-23 |
2005-05-19 |
山之内製薬株式会社 |
キノキサリン化合物
|
|
US20040023961A1
(en)
|
2002-02-11 |
2004-02-05 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenisis inhibiting activity
|
|
AU2003218462A1
(en)
|
2002-10-01 |
2004-04-23 |
Merck And Co., Inc. |
Treatment of obesity and other disorders associated with excessive food intake
|
|
DE602004016831D1
(de)
|
2003-03-17 |
2008-11-13 |
Affinium Pharm Inc |
Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
|
|
CA2536293A1
(en)
|
2003-08-22 |
2005-03-03 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating copd and pulmonary hypertension
|
|
JP2007504229A
(ja)
|
2003-09-02 |
2007-03-01 |
メルク エンド カムパニー インコーポレーテッド |
代謝調節型グルタミン酸受容体−５のモジュレーターとしてのビピリジルアミン類およびエーテル類
|
|
US7749999B2
(en)
|
2003-09-11 |
2010-07-06 |
Itherx Pharmaceuticals, Inc. |
Alpha-ketoamides and derivatives thereof
|
|
KR20070057822A
(ko)
|
2004-08-09 |
2007-06-07 |
아스텔라스세이야쿠 가부시키가이샤 |
히스톤 디아세틸라제 (ｈｄａｃ) 억제제 활성을 갖는히드록시아미드 화합물
|
|
KR20080045266A
(ko)
|
2005-09-06 |
2008-05-22 |
스미스클라인 비참 코포레이션 |
벤즈이미다졸 티오펜을 제조하기 위한 위치선택적인 방법
|
|
CN101331126A
(zh)
|
2005-09-06 |
2008-12-24 |
史密丝克莱恩比彻姆公司 |
作为plk调节剂的苯并咪唑噻吩化合物
|
|
US20070149508A1
(en)
|
2005-11-02 |
2007-06-28 |
Targegen, Inc. |
Six membered heteroaromatic inhibitors targeting resistant kinase mutations
|
|
WO2007058990A2
(en)
|
2005-11-14 |
2007-05-24 |
Kemia, Inc. |
Therapy using cytokine inhibitors
|
|
JP5015172B2
(ja)
|
2005-12-23 |
2012-08-29 |
エフ．ホフマン−ラ ロシュ アーゲー |
アリール−イソオキサゾロ−４−イル−オキサジアゾール誘導体
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
KR20080091297A
(ko)
|
2006-02-07 |
2008-10-09 |
아스텔라스세이야쿠 가부시키가이샤 |
Ｎ-히드록시아크릴아미드 화합물
|
|
CN101384586A
(zh)
*
|
2006-02-14 |
2009-03-11 |
诺华公司 |
Pi-3激酶抑制剂及其应用方法
|
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
|
US7855194B2
(en)
|
2006-03-27 |
2010-12-21 |
Hoffmann-La Roche Inc. |
Pyrimidine, quinazoline, pteridine and triazine derivatives
|
|
US7615643B2
(en)
|
2006-06-02 |
2009-11-10 |
Smithkline Beecham Corporation |
Benzimidazole thiophene compounds
|
|
PE20080710A1
(es)
|
2006-06-02 |
2008-08-07 |
Smithkline Beecham Corp |
Compuestos de tiofeno de bencimidazol
|
|
CA2691214A1
(en)
|
2006-06-09 |
2007-12-21 |
Kemia, Inc. |
Therapy using cytokine inhibitors
|
|
DE102007007751A1
(de)
|
2007-02-16 |
2008-08-21 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
AR067326A1
(es)
|
2007-05-11 |
2009-10-07 |
Novartis Ag |
Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
|
|
DE102007035333A1
(de)
|
2007-07-27 |
2009-01-29 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
GB0719644D0
(en)
|
2007-10-05 |
2007-11-14 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
GB0720444D0
(en)
|
2007-10-18 |
2007-11-28 |
Glaxo Group Ltd |
Novel compounds
|
|
BRPI0821209A2
(pt)
|
2007-12-19 |
2019-09-24 |
Amgen Inc |
composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
|
|
US7683064B2
(en)
|
2008-02-05 |
2010-03-23 |
Roche Palo Alto Llc |
Inhibitors of Bruton's tyrosine kinase
|
|
US20100029657A1
(en)
|
2008-02-29 |
2010-02-04 |
Wyeth |
Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof
|
|
ES2552320T3
(es)
|
2008-06-24 |
2015-11-27 |
F. Hoffmann-La Roche Ag |
Nuevas piridín-2-onas y piridazín-3-onas sustituidas
|
|
EA201100078A1
(ru)
|
2008-06-25 |
2011-08-30 |
Айрм Ллк |
Производные пиримидина в качестве ингибиторов киназы
|
|
US8445505B2
(en)
|
2008-06-25 |
2013-05-21 |
Irm Llc |
Pyrimidine derivatives as kinase inhibitors
|
|
EP2321309A1
(en)
|
2008-06-25 |
2011-05-18 |
Ranbaxy Laboratories Limited |
Benzothiazoles and aza-analogues thereof use as antibacterial agents
|
|
AR073354A1
(es)
|
2008-07-31 |
2010-11-03 |
Genentech Inc |
Compuestos de pirimidina, composiciones farmaceuticas y su uso en el tratamiento del cancer.
|
|
ES2522346T3
(es)
|
2008-08-22 |
2014-11-14 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de CDK
|
|
US20110172217A1
(en)
|
2008-09-05 |
2011-07-14 |
Shionogi & Co., Ltd. |
Ring-fused morpholine derivative having pi3k-inhibiting activity
|
|
GB0821307D0
(en)
|
2008-11-21 |
2008-12-31 |
Summit Corp Plc |
Compounds for treatment of duchenne muscular dystrophy
|
|
JO2885B1
(en)
|
2008-12-22 |
2015-03-15 |
ايلي ليلي اند كومباني |
Protein kinase inhibitors
|
|
US20120040916A1
(en)
|
2008-12-22 |
2012-02-16 |
Massachusetts Institute Of Technology |
Molecular inhibitors of the wnt/beta-catenin pathway
|
|
US8299077B2
(en)
|
2009-03-02 |
2012-10-30 |
Roche Palo Alto Llc |
Inhibitors of Bruton's tyrosine kinase
|
|
CA2758149A1
(en)
|
2009-04-09 |
2010-10-14 |
Boehringer Ingelheim International Gmbh |
Inhibitors of hiv replication
|
|
NZ596487A
(en)
|
2009-06-04 |
2012-11-30 |
Novartis Ag |
1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES AND THE USE THEREOF AS PI3K INHIBITORS
|
|
AU2010259009A1
(en)
|
2009-06-08 |
2012-01-12 |
Nantbioscience, Inc. |
Triazine derivatives and their therapeutical applications
|
|
JP2013502429A
(ja)
|
2009-08-19 |
2013-01-24 |
アムビト ビオスシエンセス コルポラチオン |
ビアリール化合物及びその使用方法
|
|
WO2011021678A1
(ja)
|
2009-08-21 |
2011-02-24 |
武田薬品工業株式会社 |
縮合複素環化合物
|
|
US8815928B2
(en)
|
2009-09-11 |
2014-08-26 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
|
US8759332B2
(en)
|
2009-09-11 |
2014-06-24 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
|
US8927709B2
(en)
|
2009-09-11 |
2015-01-06 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
|
EP2475254A4
(en)
|
2009-09-11 |
2013-05-22 |
Enanta Pharm Inc |
HEPATITIS C-VIRUS HEMMER
|
|
US8703938B2
(en)
|
2009-09-11 |
2014-04-22 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
|
US8822700B2
(en)
|
2009-09-11 |
2014-09-02 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
|
US9180127B2
(en)
|
2009-12-29 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
WO2011130232A1
(en)
|
2010-04-13 |
2011-10-20 |
Novartis Ag |
Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
|
|
CN103221408A
(zh)
|
2010-09-13 |
2013-07-24 |
诺瓦提斯公司 |
三嗪-*二唑类化合物
|
|
WO2012045124A1
(en)
|
2010-10-08 |
2012-04-12 |
Biota Europe Ltd |
Bacteria topoisomerase ii inhibiting 2-ethylcarbamoylamino-1, 3-benzothiazol-5-yls
|
|
WO2012095781A1
(en)
|
2011-01-13 |
2012-07-19 |
Pfizer Limited |
Indazole derivatives as sodium channel inhibitors
|
|
CN102617548A
(zh)
|
2011-01-31 |
2012-08-01 |
北京赛林泰医药技术有限公司 |
作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用
|
|
CA2836417A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Azaindole derivatives as tyrosine kinase inhibitors
|
|
EP2763976B1
(en)
|
2011-10-05 |
2016-05-18 |
Merck Sharp & Dohme Corp. |
2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
|
|
WO2013106614A1
(en)
|
2012-01-13 |
2013-07-18 |
Bristol-Myers Squibb Company |
Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
|
|
EP2802576B1
(en)
|
2012-01-13 |
2018-06-27 |
Bristol-Myers Squibb Company |
Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
|
|
CN104254533B
(zh)
|
2012-01-13 |
2017-09-08 |
百时美施贵宝公司 |
用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物
|
|
PT2840080T
(pt)
|
2012-04-17 |
2018-02-06 |
Fujifilm Corp |
Composto heterocíclico que contém azoto ou sal do mesmo
|
|
EP2863916B1
(en)
|
2012-06-22 |
2018-07-18 |
Merck Sharp & Dohme Corp. |
Substituted pyridine spleen tyrosine kinase (syk) inhibitors
|
|
US8729263B2
(en)
|
2012-08-13 |
2014-05-20 |
Novartis Ag |
1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
|
|
JP2015533151A
(ja)
|
2012-10-16 |
2015-11-19 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
セリン／スレオニンキナーゼ阻害剤
|
|
WO2014106800A2
(en)
|
2013-01-04 |
2014-07-10 |
Aurigene Discovery Technologies Limited |
Substituted 2-amino pyrimidine derivatives as kinase inhibitors
|
|
TW201443037A
(zh)
|
2013-01-09 |
2014-11-16 |
Gilead Sciences Inc |
治療用化合物
|
|
JPWO2015016206A1
(ja)
|
2013-07-30 |
2017-03-02 |
武田薬品工業株式会社 |
複素環化合物
|
|
WO2015098991A1
(ja)
|
2013-12-26 |
2015-07-02 |
東レ株式会社 |
Ｎ－アルキルアミド誘導体及びその医薬用途
|
|
WO2015112441A1
(en)
|
2014-01-22 |
2015-07-30 |
Merck Sharp & Dohme Corp. |
Metallo-beta-lactamase inhibitors
|
|
WO2015131080A1
(en)
|
2014-02-28 |
2015-09-03 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
RU2671494C2
(ru)
|
2014-05-28 |
2018-11-01 |
Шанхай Фокон Фармасьютикал Ко., Лтд |
Некоторые ингибиторы протеинкиназы
|
|
CN105294655B
(zh)
|
2014-07-26 |
2019-03-15 |
广东东阳光药业有限公司 |
Cdk类小分子抑制剂的化合物及其用途
|
|
WO2016022644A1
(en)
|
2014-08-06 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
Heterocyclic cgrp receptor antagonists
|
|
WO2016027904A1
(ja)
|
2014-08-22 |
2016-02-25 |
富士フイルム株式会社 |
Ｆｌｔ３変異陽性癌を処置するための医薬組成物、変異型ｆｌｔ３阻害剤およびそれらの応用
|
|
JP6646044B2
(ja)
|
2014-09-12 |
2020-02-14 |
ノバルティス アーゲー |
キナーゼ阻害剤としての化合物および組成物
|
|
US10472346B2
(en)
|
2014-10-31 |
2019-11-12 |
The General Hospital Corporation |
Potent gamma-secretase modulators
|
|
WO2016089208A2
(en)
|
2014-12-04 |
2016-06-09 |
Stichting Maastricht Radiation Oncology "Maastro-Clinic" |
Sulfonamide, sulfamate and sulfamide derivatives of anti-cancer agents
|
|
EP3053577A1
(en)
|
2015-02-09 |
2016-08-10 |
F. Hoffmann-La Roche AG |
Compounds for the treatment of cancer
|
|
EP3256126B1
(en)
|
2015-02-09 |
2024-03-27 |
F. Hoffmann-La Roche AG |
Compounds for the treatment of cancer
|
|
EP3262049B1
(en)
|
2015-02-27 |
2022-07-20 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
PH12017501822B1
(en)
|
2015-04-14 |
2022-05-04 |
Lead Discovery Center Gmbh |
Quinoline derivatives as tam rtk inhibitors
|
|
DK3305785T3
(da)
*
|
2015-05-29 |
2021-10-11 |
Teijin Pharma Ltd |
Pyrido[3,4-d]pyrimidinderivat og farmaceutisk acceptabelt salt deraf
|
|
EP3313530B1
(en)
|
2015-06-26 |
2022-10-05 |
Dana Farber Cancer Institute, Inc. |
4,6-pyrimidinylene derivatives and uses thereof
|
|
US10829484B2
(en)
|
2015-07-28 |
2020-11-10 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
CN106608879A
(zh)
|
2015-10-27 |
2017-05-03 |
甘李药业股份有限公司 |
一种蛋白激酶抑制剂及其制备方法和医药用途
|
|
EA201800367A1
(ru)
|
2015-12-10 |
2019-02-28 |
ПиТиСи ТЕРАПЬЮТИКС, ИНК. |
Способы лечения болезни хантингтона
|
|
US11225492B2
(en)
|
2015-12-13 |
2022-01-18 |
Hangzhou Innogate Pharma Co., Ltd. |
Heterocycles useful as anti-cancer agents
|
|
WO2017161045A1
(en)
|
2016-03-16 |
2017-09-21 |
Plexxikon Inc. |
Compounds and methods for kinase modulation and indications therefore
|
|
WO2017185031A1
(en)
|
2016-04-22 |
2017-10-26 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
|
|
KR102498741B1
(ko)
|
2016-04-29 |
2023-02-10 |
에프지에이치 바이오테크 인코포레이티드 |
질환 치료용 이-치환된 피라졸 화합물
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
CN112250669B
(zh)
|
2016-09-07 |
2022-02-25 |
江苏豪森药业集团有限公司 |
苯并咪唑类化合物激酶抑制剂及其制备方法和应用
|
|
JP2020514252A
(ja)
|
2016-12-08 |
2020-05-21 |
アイカーン スクール オブ メディスン アット マウント シナイ |
Ｃｄｋ４／６媒介性がんを治療するための組成物および方法
|
|
US10703757B2
(en)
|
2016-12-23 |
2020-07-07 |
Plexxikon Inc. |
Compounds and methods for CDK8 modulation and indications therefor
|
|
JP7249950B2
(ja)
|
2017-03-27 |
2023-03-31 |
カーデュリオン・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー |
ヘテロ環化合物
|
|
JP7175026B2
(ja)
|
2017-04-01 |
2022-11-18 |
晟科薬業（江蘇）有限公司 |
プロテインキナーゼ阻害剤としての１ｈ－イミダゾ［４，５－ｈ］キナゾリン系化合物
|
|
JP2020523365A
(ja)
|
2017-06-14 |
2020-08-06 |
ピーティーシー セラピューティクス，インコーポレーテッド |
Ｒｎａスプライシングを改変する方法
|
|
CN109516989B
(zh)
|
2017-09-17 |
2021-12-31 |
上海美志医药科技有限公司 |
一类抑制并降解cdk的化合物
|
|
IL310346A
(en)
|
2017-10-20 |
2024-03-01 |
Univ Vanderbilt |
Muscarinic acetylcholine M4 receptor antagonists
|
|
JP7167146B2
(ja)
|
2017-11-06 |
2022-11-08 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｈｐｋ１阻害剤として有用なイソフラノン化合物
|
|
EP3732163A4
(en)
|
2017-12-20 |
2021-07-14 |
Vanderbilt University |
MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS
|
|
ES2971712T3
(es)
|
2017-12-22 |
2024-06-06 |
Hibercell Inc |
Derivados de cromenopiridina como inhibidores de la fosfatidilinositol fosfato cinasa
|
|
EP3728228A1
(en)
|
2017-12-22 |
2020-10-28 |
Ravenna Pharmaceuticals, Inc. |
Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
|
|
BR112020012651A2
(pt)
|
2017-12-22 |
2020-12-01 |
Ravenna Pharmaceuticals, Inc. |
compostos derivados de aril-bipiridina amina como inibidores da fosfatidilinositol fosfato quinase, composição farmacêutica compreendendo os mesmos e usos terapêuticos dos ditos compostos
|
|
CN111788182B
(zh)
|
2018-02-02 |
2023-09-26 |
范德堡大学 |
毒蕈碱性乙酰胆碱受体m4的拮抗剂
|
|
WO2019161224A1
(en)
*
|
2018-02-15 |
2019-08-22 |
GiraFpharma LLC |
Heterocyclic compounds as kinase inhibitors
|
|
EA202092001A1
(ru)
|
2018-03-27 |
2021-01-29 |
ПиТиСи ТЕРАПЬЮТИКС, ИНК. |
Соединения для лечения болезни гентингтона
|
|
US12037323B2
(en)
|
2018-05-03 |
2024-07-16 |
Bristol-Myers Squibb Company |
Uracil derivatives as Mer-AXL inhibitors
|
|
HRP20240935T1
(hr)
|
2018-06-27 |
2024-11-22 |
Ptc Therapeutics, Inc. |
Heterociklični i heteroaril spojevi za liječenje huntingtonove bolesti
|
|
WO2020023480A1
(en)
|
2018-07-23 |
2020-01-30 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
|
|
JP7600123B2
(ja)
|
2018-10-15 |
2024-12-16 |
ニューリックス セラピューティクス，インコーポレイテッド |
ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物
|
|
CA3118908A1
(en)
*
|
2018-11-06 |
2020-05-14 |
Edgewise Therapeutics, Inc. |
Pyridazinone compounds and uses thereof
|
|
WO2020109191A1
(en)
|
2018-11-27 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Aryl compounds for the treatment and prophylaxis of bacterial infection
|
|
WO2020108661A1
(zh)
|
2018-11-30 |
2020-06-04 |
杭州英创医药科技有限公司 |
作为cdk-hdac双通路抑制剂的杂环化合物
|
|
CN113166148B
(zh)
|
2018-12-07 |
2024-04-12 |
杭州英创医药科技有限公司 |
作为cdk-hdac双通路抑制剂的杂环化合物
|
|
AU2019392232B2
(en)
|
2018-12-07 |
2025-02-13 |
Sunshine Lake Pharma Co., Ltd. |
RET inhibitors, pharmaceutical compositions and uses thereof
|
|
WO2020132700A1
(en)
|
2018-12-21 |
2020-06-25 |
Fgh Biotech Inc. |
Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
|
|
BR112021011861A2
(pt)
|
2019-01-04 |
2021-09-08 |
Praxis Biotech LLC |
Inibidores da proteína de ativação de fibroblastos
|
|
JP2022519311A
(ja)
|
2019-02-05 |
2022-03-22 |
スカイホーク・セラピューティクス・インコーポレーテッド |
スプライシングを調節するための方法および組成物
|
|
JP7603595B2
(ja)
|
2019-02-06 |
2024-12-20 |
スカイホーク・セラピューティクス・インコーポレーテッド |
スプライシングを調節するための方法および組成物
|
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
|
CN113661164B
(zh)
|
2019-04-08 |
2025-03-04 |
珠海宇繁生物科技有限责任公司 |
一种cdk激酶抑制剂及其应用
|
|
MX2021013531A
(es)
|
2019-05-05 |
2022-02-11 |
Qilu Regor Therapeutics Inc |
Inhibidores de cdk.
|
|
JP7649257B2
(ja)
|
2019-05-13 |
2025-03-19 |
ピーティーシー セラピューティクス， インコーポレイテッド |
ハンチントン病を処置するための化合物
|
|
TW202112784A
(zh)
|
2019-06-17 |
2021-04-01 |
美商佩特拉製藥公司 |
作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物
|
|
TW202112767A
(zh)
|
2019-06-17 |
2021-04-01 |
美商佩特拉製藥公司 |
作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
|